Who is eligible for clinical trial NCT07784959?

Participants must meet the protocol's inclusion criteria for ALK Positive. Confirm all requirements with the study coordinator.

Does clinical trial NCT07784959 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-20

Study of NXP900 With Lorlatinib in ALK+ Lung Cancer (NCT07784959)

A Phase 1b Clinical Study of NXP900 in Combination With Lorlatinib in Subjects With Advanced, ALK-positive, Non-Small Cell Lung Cancer

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Nuvectis Pharma, Inc.

🩺 Plain-English Summary (8th-Grade Level)

This is a multi-center, open label, Phase 1b study of NXP900 in combination with lorlatinib in subjects with advanced, ALK-positive non-small cell lung cancer (NSCLC)

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (3 items).

Location: NEXT Virginia — Fairfax, Virginia

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

18 years old or older
Unresectable, metastatic or locally advanced ALK-positive NSCLC.
Must have received lorlatinib as first or second line TKI
One prior line of systemic chemotherapy is permitted
Must have tolerated the dose level of lorlatinib actively being explored in the study or a higher dose

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Known single or compound ALK domain mutations that cause resistance to lorlatinib, or known actionable oncogenic driver alterations other than ALK with approved targeted therapies available, such as, MET or EGFR mutations or HER2 overexpression
Any contraindications to treatment with lorlatinib according to the lorlatinib United States Prescribing Information (USPI)

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

NEXT Virginia — Fairfax, Virginia

📞 Contact the Study Coordinator

Phone: (201) 627-8129

Email: ebelshaw@nuvectis.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in ALK Positive

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer — Houston, Texas

Explore by condition: All ALK Positive clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗